@article {Pazdur:1998:0167-6997:341, author = "Pazdur R.", author = "Medgyesy D.C.", author = "Winn R.J.", author = "Dakhil S.R.", author = "Moore Jr D.F.", author = "Scalzo A.", author = "Hoff P.M.", author = "Arbuck S.G.", author = "Abbruzzese J.L.", title = "Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma", journal = "Investigational New Drugs", volume = "16", year = "1998", abstract = "

9-Aminocamptothecin (9-AC) is a camptothecin derivative with broad antitumor activity in preclinical studies. Prior investigations suggested that prolonged maintenance of 9-AC lactone plasma concentrations above 10 nmol/l and frequent administration of the drug are important determinants of antitumor activity. Our phase II study, therefore, examined a 5-day continuous infusion of 9-AC weekly for 3 weeks in patients with advanced colorectal cancer. Eighteen patients previously untreated for metastatic disease received 480 mgr g/m^2/day of 9-AC. No responses were observed in 17 evaluable patients. Severe toxicities included granulocytopenia, nausea, vomiting and diarrhea. The median absolute granulocyte count (AGC) nadir was 2,300/ mgr l (range 0–9,000/ mgr l) and occurred on day 10. Eight patients received an escalated dose of 600 mgr g/m^2/day. The median AGC nadir at the escalated dose was 1,500/ mgr l (range: 300–2,700/ mgr l) and occurred on day 22. The median number of courses given was 2 (range: 1–8); and the median time to disease progression was 8 weeks (range: 1–40 weeks). 9-AC administered by this schedule lacked antitumor activity in patients with advanced colorectal carcinomas.

", pages = "341-346(6)", url = "http://www.ingentaconnect.com/content/klu/drug/1998/00000016/00000004/00207259" }